Cohance Lifesciences ESOP Grants 19.75M Options

COHANCE

The Nomination and Remuneration Committee at its meeting held on 23 July 2026 approved the following:

Taking on record the in-principle approvals issued by BSE Limited and National Stock Exchange of India Limited for the Cohance Lifesciences Limited – Employee Stock Option Plan, 2026 (ESOP 2026), vide their letters dated 21 July 2026
Grant of up to 1,97,48,317 stock options to eligible employees under ESOP 2026
Grant of 1,74,843 stock options to eligible employees under Suven Pharmaceuticals Limited – Employee Stock Option Plan – 2023 (ESOP 2023)
Allotment of 30,190 equity shares of face value of ₹1 each fully paid-up to options grantees who exercised vested options under ESOP 2023
Cancellation of 1,87,703 stock options from the grant of 1,98,711 stock options made on 13 March 2026 under ESOP 2023

Total options granted: Up to 1,97,48,317 employee stock options
Each option convertible into one equity share of face value of ₹1
Scheme compliant with SEBI (SBEB) Regulations, 2021
Total shares covered: 1,97,48,317
Pricing formula: Exercise price per option decided by board or nomination and remuneration committee
For grants within 6 months of stock exchange approval: Not less than ₹325
For grants to existing employees made within 10 working days of approval: Exercise price of ₹325
For grants after 6 months: Not more than 20% discount to 21-day average market price
ESOP 2026 was approved by postal ballot by the Company on 13 June 2026

Options granted: 1,74,843 employee stock options
Each option convertible into one equity share of face value of ₹1
Scheme compliant with SEBI (SBEB) Regulations, 2021
Total shares covered: 1,74,843
Exercise price: ₹495 for all options
Vesting period: Minimum 1 year, maximum 10 years from grant date
Exercise period: Up to 3 years from vesting date
Additional cancellations approved: Up to 17,90,532 employee stock options under ESOP 2023 pursuant to voluntary surrender by employees